- 1 Genetic newborn screening stakeholder perspectives.
- 2 Didu Kariyawasam^{12*}, Joanne Scarfe (joint first authors)³, Christian Meagher², Michelle A.
- 3 Farrar ^{1, 2}, Kaustav Bhattacharya ²⁴⁵, Stacy M. Carter⁶, Ainsley J. Newson⁷, Margaret
- 4 Otlowski⁸, Jo Watson⁹, Nicole Millis¹⁰, Sarah Norris³
- ⁵ ¹Department of Neurology, Sydney Children's Hospital Network, Sydney, NSW, Australia
- 6 ²Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine
- 7 and Health, UNSW Sydney, Sydney, NSW, Australia
- ⁸ ³The University of Sydney, Faculty of Medicine and Health, Sydney School of Public Health,
- 9 Menzies Centre for Health Policy & Economics, NSW, Australia
- ⁴Genetic Metabolic Disorders Service. Sydney Children's Hospital Network, Randwick and
- 11 Westmead, NSW, Australia
- ⁵Faculty of Medicine and Health, Discipline of Genomics, Sydney University, Westmead,
- 13 NSW, Australia
- ⁶Australian Centre for Health Engagement, Evidence and Values, School of Health and
- 15 Society, The University of Wollongong, Wollongong, NSW, Australia
- ⁷Sydney Health Ethics, Sydney School of Public Health, Faculty of Medicine and Health, The
- 17 University of Sydney, Sydney, NSW, Australia
- 18 ⁸Centre for Law and Genetics, Faculty of Law, College of Arts, Law and Education,
- 19 University of Tasmania, Tasmania, Australia
- ⁹HTA Consumer Consultative Committee, Department of Health & Aged Care, Canberra,
- 21 ACT, Australia
- 22 ¹⁰ Rare Voices Australia, Mentone, VIC, Australia
- 23 NOTE: This reprint we not be used to guide clinical practice.

45 ABSTRACT

46 Background

Newborn bloodspot screening is a well-established population health initiative that detects 47 serious, childhood-onset, treatable conditions to improve health outcomes. With genomic 48 technologies advancing rapidly, many countries are actively discussing the introduction of 49 genomic assays into newborn screening programs. While adding genomic testing to 50 Australia's newborn screening program could improve outcomes for infants and families, it 51 must be considered against potential harms, ethical, legal, equity and social implications, and 52 economic and health system impacts. We must ask not only '*can*' we use genomics to screen 53 newborns?' but 'should we'?' and 'how much should health systems invest in genomic 54 newborn screening?'. 55

56 Methods

This study will use qualitative methods to explore understanding, priorities, concerns and 57 expectations of genomic newborn screening among parents/carers, health 58 professionals/scientists, and health policy makers across Australia. In-depth, semi-structured 59 interviews will be held with 30-40 parents/carers recruited via hospital and community 60 61 settings, 15-20 health professionals/scientists, and 10-15 health policy makers. Data will be analysed using inductive content analysis. The Sydney Children's Hospital Network Human 62 Research Ethics Committee approved this study protocol [2023/ETH02371]. The Standards 63 64 for Reporting Qualitative Research will guide study planning, conduct and reporting.

65

66

68 Discussion

69	Few studies have engaged a diverse range of stakeholders to explore the implications of
70	genomics in newborn screening in a culturally and genetically diverse population, nor in a
71	health system underpinned by universal health care. As the first study within a multi-part
72	research program, findings will be used to generate new knowledge on the risks and benefits
73	and importance of ethical, legal, social and equity implications of genomic newborn
74	screening from the perspective of key stakeholders. As such it will be the foundation on
75	which child and family centered criteria can be developed to inform health technology
76	assessments and drive efficient and effective policy decision-making on the implementation
77	of genomics in newborn screening.
78	Keywords: Genomics, newborn bloodspot screening, benefits and harms, parents, policy,
79	health professionals, interview, health technology assessment, ethics, legal issues, qualitative
80	research.
81	
82	
02	
83	
84	
85	
86	
80	
87	
88	
89	

90 INTRODUCTION

Newborn bloodspot screening (NBS) is at an inflexion point in its evolution. A population 91 health initiative, it has a historical mandate to identify newborns at risk of serious, childhood 92 onset and usually treatable conditions, traditionally through analysis of biochemical 93 indicators (1). The rapid advancement of genomic capabilities with the advent of next 94 95 generation DNA sequencing methods has led to substantial interest amongst stakeholders to leverage these technologies within NBS ('genomic NBS'). While the precise ways in which 96 genomic NBS could be deployed are yet to be determined, a key artefact of any move to the 97 use of genomics in NBS, is the potential to screen for many more genetic conditions than 98 presently (2), with the goal of shortening an often arduous and complex diagnostic journey 99 for affected individuals and their families (3). Avoiding a diagnostic odyssey is especially 100 101 relevant for the diagnostically challenging 7000 or so rare non-communicable, genetic conditions (4), which collectively affect 8% of the Australian population, equivalent to 2 102 million individuals (5). For those affected with these conditions, there is typically a high 103 level of symptom complexity conferring a significant health and psycho-social challenge, in 104 part secondary to the accumulation of comorbidities associated with often delayed diagnosis. 105 106 Identifying an increased risk of a genetic conditions through genomic NBS may lead to a timely diagnosis. A timely diagnosis, in turn, could enable expedient access to medical 107 108 interventions and participation in research, facilitate early engagement with support, care and disability services and allow for financial and reproductive planning for affected families (6). 109 Cumulatively, the effects of receiving an early diagnosis are manifold but essentially seek to 110 improve health and psychosocial outcomes for the screened newborn (primary benefits) and 111 as a downstream consequence, the wider family (secondary benefits) (1, 6). 112

113 These potential opportunities and benefits need to be balanced against possible harms to 114 screened newborns and their families, as well as considered against the challenges that will

arise from implementation at scale within complex health systems. If risks and barriers to
successful use of genomic NBS are not identified and proactively addressed, the
incorporation of genomics may lead to the erosion of an established and highly successful
screening program (7). Moreover, it may risk existing high public trust in, and uptake of,
NBS (8).

120 Proposed and implemented strategies for genomic NBS include identifying variations in single genes within first tier analysis (as deployed for NBS in spinal muscular atrophy) (9), 121 using genomics as second tier screening for children with biochemical signatures of disease 122 to reduce false positive rates (as proposed for NBS in Duchenne muscular dystrophy) (10). 123 the use of targeted gene panels of varying sizes (11), or even whole exome or genome 124 sequencing techniques for use as a health resource throughout one's life (2, 12). For exome or 125 genome sequencing techniques in particular, gaps in knowledge remain regarding their 126 utility, cost effectiveness and feasibility for use at a population level. 127

Since 2022, the Medical Services Advisory Committee (MSAC), an Australian body that 128 considers the addition of new conditions onto routine national NBS panels has evaluated and 129 130 endorsed the use of first tier genetic technologies X-linked adrenoleukodystrophy, and continues to assess genomic NBS for a growing number of conditions ranging from 131 hemoglobinopathies to lysosomal disorders (13). In line with the prevailing policy and 132 133 international practice, MSAC continues to take what may be termed as a 'condition led' approach, as opposed to a 'technology led' approach to facilitate health technology 134 assessments within newborn screening (14, 15). As such, conditions are individually 135 136 evaluated for NBS endorsement through processes such as health technology assessments (HTAs). These processes focus on clinical and cost-effectiveness aspects of population 137 screening, underpinned by evidence of test performance (rates of true/false positives and 138

true/false negatives), acceptability of treatments for those identified as at risk through NBS, 139 and an agreed policy on who, how and when to treat, often generated through pilot (NBS) 140 programs that run over the course of many years (16). The creation of a robust evidence-base 141 to inform these outcomes is time consuming, requires significant clinical research 142 infrastructure and is especially challenging for rare diseases. Here, the development and 143 application of HTA criteria is adversely impacted by small patient numbers within each 144 condition, the lack of a coordinated strategy for data collection and synthesis, and less clinical 145 evidence being available due to the challenges of conducting large scale clinical trials (17, 146 147 18). Furthermore, whilst HTAs recognise ethical, legal and equity aspects of genomics (including some early consideration of its role in population screening) these factors are 148 currently only minimally integrated into the assessment processes (19). This is in contrast to 149 150 growing support for incorporating such components early into health policy decision-making processes by stakeholders (20), reflecting an emerging paradigm of genomic NBS as a health 151 intervention that is part of a 'sociotechnical network' of people and technologies, not separate 152 from but requiring integration with clinical evidence of utility and incremental benefit from 153 existing models of diagnosis and clinical care (21). 154

155 For future NBS programs to be flexible to accommodate the appropriate introduction of new health technologies such as genomics, decision-making must be efficient, robust and 156 157 informed by all available evidence whilst also being contextualised for the specific challenges shared by many rare diseases (22), facilitated by the integration of real-world evidence, 158 combined with expert input, clinical merit and public consultation (23). In tandem and in line 159 with national policy, evaluating stakeholder perspectives of risk-benefit can help us 160 understand the power and pitfalls of genomic capabilities in NBS, and inform a patient-driven 161 and personalized model of care (24), (15). Synthesising stakeholder perspectives offers 162 significant knowledge benefits including identification of conceivable benefits, risks, barriers 163

and enablers of implementation. This evidence generation can help to streamline support and
access to care by enabling co-design of an effective and holistic model of screening,
diagnostic and clinical management. Concomitantly, this foundation may help to inform NBS
policy and practice that is equitable, ethically appropriate and adapted to meet the needs of
newborns and their families(15).

169 Whilst some of these issues have been explored in health systems with large private health insurance funding models, namely in North America (25-27), there is paucity of research on 170 stakeholder perspectives of genomic NBS within health domains that are predominantly 171 publicly funded, cover wide geographical expanses characteristic of the Australasian region, 172 and encompass socio-demographically heterogenous (including Indigenous) populations. In 173 Australia, while there has been a degree of systematic synthesis of information on genomic 174 NBS from the perspective of the lay public (26, 28), and from rare disease medical experts 175 (29, 30), the attitudes of parents of children with heterogenous genetic conditions (diagnosed 176 177 with and without NBS) have not been analysed, nor have the unique challenges faced by policy makers when considering whether and how to incorporate genomics into NBS (31). 178

This study forms the first part of gEnomics4newborns research project: Integrating Ethics and 179 Equity with Economics and Effectiveness for genomics in newborn screening (MRF2015965) 180 (Figure 1). Accordingly, it will create knowledge on the perceived risks and benefits, barriers 181 and facilitators of implementation of genomic NBS within an Australian context. This study 182 will underpin the creation of a policy resource that will define key criteria for the assessment 183 of new conditions onto routine NBS panels (screened through genetic technologies). 184 185 Uniquely, this study will begin to inform policy decision makers on the priorities and relative importance of equity, ethical, legal, and social factors from a stakeholder perspective and 186

- 187 how these can be incorporated into HTAs to maximise benefit, whilst mitigating harms of
- 188 genomic technologies on a population level.

189			
190			
191			
192			
193			
194			
195			
196			
197			
198			
199			
200			
201			
202			
203			
204			

Figure 1. Placing the current study as the foundation of a research program to integrate ethical, legal, social and equity factors into health technology decision-making for genomic newborn screening.

209	*Stakeholders include: Parents/carers, health care professionals/scientists, health policy makers.
210	**Includes: Best-worst case scaling, Citizen's Jury and Yarning Circle.
211	Evidence generated through engagement with stakeholders will provide essential knowledge for a
212	multimodal approach to generating recommendations. This will involve: 1. Best-worst case scaling, a
213	process through which choice data from individuals is collated to understand choice processes using a
214	top to bottom ranking method, 2. Citizen's Jury, a deliberative inclusive approach to engaging with
215	the community on complex issues. This process supports a group of randomly selected
216	demographically diverse 'jurors' to hear and examine information given by expert witnesses on the
217	complexities of genomics in NBS, and then to make recommendations about how policy makers
218	should approach genomic NBS health technology assessment, 3. Yarning Circles, an established
219	process of dialogue used within Aboriginal and Torres Strait Islander culture to assimilate and weigh
220	information. This multimodal approach will lead to development of Assessment Criteria that can be
221	used by future policy makers to establish methods of assessing new conditions in a faster, less
222	resource-intensive manner and incorporating ethical, legal, social and equity aspects of genomic NBS.
223	
224	
225	
226	
227	
228	

229 AIM

230	This study aims to explore stakeholders' understanding, attitudes, concerns, and priorities
231	related to genomic NBS in Australia. These stakeholders include parents and carers who have
232	participated in NBS who have had one or more children diagnosed with genetic conditions,
233	and those who have received false positive, false negative and uncertain newborn screen
234	results; health care professionals and scientists; and health policy makers. This study will
235	investigate a diverse range of perspectives on current and future impacts of the use of
236	genomics in NBS, including the ethical, legal, social and equity implications, and explore
237	how these views merge or diverge.

238 METHODS

239 Ethics approval

Ethics approval for the study is provided by the Sydney Children's Hospital Network HumanResearch Ethics Committee [2023/ETH02371].

242 Study design

243 This is a co-designed multi-cohort qualitative study using semi-structured interviews to explore understanding, experiences, and expectations of the potential use of genomics in NBS 244 among parents/carers, health professionals and scientists, and health policy makers across 245 Australia. Interview guides were developed following a scoping literature review of genomics 246 in NBS, as well as input from the broader gEnomics4newborns stakeholders who have 247 expertise in health and policy, clinical practice, consumer advisory and rare diseases 248 advocacy groups. The full interview guides are included as Supplementary Material (S1 249 Appendix). In-depth, semi-structured individual and dyadic interviews will be held with 250 parents and carers (n=30-40 participants), and individual interviews will be conducted with 251 health professionals and scientists (n=15-20) and health policy makers (n=10-15). A thematic 252

summary of the interview guides follows (Table 1). The Standards for Reporting Qualitative

Research (SRQR) are being employed from study planning to conduct and reporting. (32).

278 Table 1. Thematic summary of interview guides

Domain	Discussion topics				
Parents / Carers – Cohort 1a (i) and 1b					
Experience of child's condition	Condition type and characteristics				
Achieving a diagnosis	Experience of achieving a diagnosis through NBS				
	Experience of achieving a diagnosis outside of NBS				
Care and management	Care and management of condition				
	Impact of condition on child and family				
Parents/Carers – Cohort	la (ii)				
Experience of NBS	Experiences of participating in NBS				
	Experience of receiving a false positive or false negative NBS result				
	Perspectives on NBS following false positive or false negative result				
All parent/carer cohorts					
Genomic NBS	Understanding and interpretation of genomic NBS				
	Perceived risks of genomic NBS				
	Minimising harm to families through genomic NBS				
	Inclusion of conditions in genomic NBS				
Model of care for genomic NBS	Consent to participate in genomic NBS				
	Delivery of results				
	Receiving uncertain results				
	Supporting families through achieving a screening result and diagnosis				
	Influence of genomics on acceptability of NBS as a public health program				
Health professionals / Scie	entists				
Professional experience	General				
	NBS and genetic diseases				
	Genomic sequencing				
Genomic NBS	Perspectives on incorporating genomics into NBS				
	Included conditions				
	Perspectives on potential benefits and harms				

	Ethical, legal and equity considerations
	Policy and implementation
Policy makers	
Professional experience	Professional field
Genomic NBS	Views on the use of genomics in population screening and in NBS specifically
	Perceived impact of genomics on current Australian NBS programs
	Perceived benefits and challenges of genomic NBS
Genomic NBS policy	Impact on National Policy Framework
	Views on current processes and required information when assessing genomic NBS
	Ethical, legal, social and equity considerations
Genomic NBS implementation	Implementation challenges and perceived solutions
	Impact of genomic NBS on parents/carers and families

289 Sample and recruitment

Purposive sampling will be used to select participants and capture diversity in participant 290 characteristics, including a range of (positive and negative) experiences across NBS and 291 diagnosis. The number of participants will be determined through an iterative process of data 292 collection, analysis and reflection, with data collected until theoretical saturation is reached 293 294 and a range of perspectives are captured across participant types (33). Parents and carers of children diagnosed with a genetic condition, and parents and carers of children who received 295 296 a false positive NBS result will be invited to participate in either individual or joint interviews with the other parent/carer of the child (defined as participant dyads). They will be 297 recruited from hospital and community settings. All participants within this study are adults 298 >18 years of age. 299

The study will recruit participants across a range of genders, sociodemographics and timing of screening and/or diagnosis. Non-English speakers will be supported by language interpreter services. Participants who identify as Aboriginal and/or Torres Strait Islander will be included in the study as they appear incidentally in the sample. These participants will be supported by the Aboriginal Hospital Liaison Officer and Aboriginal and Torres Strait Islander support services. Four cohorts will be recruited into the study:

306

Cohort 1a Parents or carers who have participated in NBS in Australia and have: (i) children diagnosed within NBS programs with genetic conditions included in the current NBS Policy Framework (parents/carers of true screen positive individuals i.e. NBS screen positive and children go on to be diagnostically confirmed to have the condition) (17); or (ii) experienced false or uncertain results: a false positive result (NBS screen is positive but the child is NOT confirmed to have a genetic condition), a false negative result (NBS screen is negative for the named condition but the child develops symptoms of a condition and is later confirmed to

have a genetic diagnosis) or a screen result with uncertain significance (i.e. those where thereare variants of unknown clinical significance in disease causing genes).

316 *Exclusion criteria*

Parents/carers of children receiving a true screen negative result (parents/carers of individuals who are screened negative for conditions on the newborn screening panel and do not go on to be diagnosed with the condition at the time of the study) are excluded from the cohort, as the views of these individuals have been explored in previous research (34), and will also be captured in the other studies within the research program.

322

Cohort 1b. Parents or carers of children diagnosed with a genetic condition that would be
unlikely to be (or has not been) approved under the current Australian NBS Policy
Framework and associated decision-making pathways. Parents and carers who have been
determined by their clinician to be at high risk of significant psychological distress by
participating in the study will be excluded.

For these cohorts, clinicians from Sydney Children's Hospital Network (SCHN) will pre-328 screen, select, contact, and obtain consent to be contacted by researchers from eligible 329 participants from their clinical patient databases for parents/carers in Cohorts 1a and 1b. The 330 managing clinician will be invited to put forward the name and contact details of participants 331 who consent to be contacted to the study team. Potential participants will also be invited to 332 333 enrol by study investigators when they are attending SCHN for routine clinical appointments as part of clinical care, where the managing clinician will obtain consent from prospective 334 participants for the study team to contact them. To ensure diversity of opinions from across 335 the community, patient advocacy and support organisations will also be approached to 336 distribute advertisements for participation in the study via email and social media. 337 Recruitment will be facilitated by partner consumer advocacy organisations in the rare 338

disease community, the study's Consumer Advisory Group, and project investigators. 339 Parents/carers of children who received a false positive or false negative NBS result will be 340 recruited via SCHN clinical databases. To avoid conflicts of interest, study investigators 341 outside of the managing clinical team will recruit individuals into the study. 342 To ensure a diversity of opinions across the parent/carer cohorts, a recruitment screener will 343 be used following the consent process to ensure that a diversity of participants and range of 344 experiences are captured (S2 Appendix). A Decision Regret Scale will be administered 345 during the screening process to capture the extent to which participants do or do not regret 346 347 participating in newborn screening and, where relevant, consenting to their child/ren undergoing genetic testing (35). 348 Cohort 2. Health professionals (including midwives, genetic counsellors, and those 349 experienced in NBS) and scientists involved in research and clinical care of children with 350 genetic conditions and/or expertise in NBS and/or genomic medicine. Health professionals 351 and scientists will be identified by purposive sampling relating to area of practice or 352 expertise, experience, gender, age and ethnicity, with sampling aiming to represent 353 stakeholders across Australia with at least one health professional/scientist from each state. 354 Health professionals/scientists will be identified through investigator networks, contacted via 355 email, and followed up with an additional email reminder or phone call two weeks later. 356 357 Cohort 3. Policy makers across Federal and State governments involved in NBS, genomics, and/or HTA. Policy maker recruitment will be facilitated by project investigators and 358 researchers through existing networks. 359 For cohorts 2 and 3, passive snowball sampling may be used where interviewees will provide 360 names of potentially suitable colleagues and information already in the public domain will be 361

362 used to approach these individuals.

363 *Data collection*

Participants will take part in a single interview conducted by one researcher either face to face at a private location within hospital sites (such as an office or family room), or by videoconferencing as preferred by the participant. Parent/carer dyads will be interviewed together where possible. The managing clinician will not interview parents/carers of patients they are currently treating. Interviews will be audio-recorded with participants' consent and will be 45-60 minutes in duration. If a participant experiences distress during or after an interview, a Psychological Distress Protocol will be implemented.

371

372 Data analysis

All recorded interviews will be transcribed verbatim and checked by the interviewer for 373 374 errors. Transcripts will be managed using qualitative data analysis software NVivo V 14 and analysed using inductive content analysis (ICA). ICA is a method of analysing data where 375 'content categories' are generated from the data (36). ICA is appropriate for use where 376 existing research is nascent, where an outcome of the research is to describe and understand 377 the area being investigated, and where the research has direct importance for policy and 378 practice (36). A proportion of early transcripts will be coded by two researchers 379 independently. Preliminary coding will be compared on an agreed inductive coding frame 380 that captures the breadth of views and experiences in the data. This coding frame will be 381 382 applied to further transcripts independently by two researchers and revised iteratively as needed. Data from consumers, health professionals, scientists, and policy makers will be 383 analysed separately, however where similar themes arise across the participant types this will 384 be reported. Parent/carer dyads will be analysed as one unit (37). Reflexivity will be 385 maintained by the research team through analysis and writing by recording, discussing, and 386

challenging assumptions derived from their cultural, personal, and professional backgrounds(32).

389 **DISCUSSION**

This will be a first-in kind study in Australia which focuses on the perspectives of genomic 390 NBS from parents/carers whose children have been diagnosed with a genetic condition (both 391 with and without NBS). Whilst previous studies have evaluated the perspectives of the public 392 and professional stakeholders on genomic NBS in Australia (34, 38), the current study seeks 393 394 to advance knowledge by assessing the perceived opportunities and challenges of using genomics in NBS amongst families with lived experiences of receiving a genetic diagnosis 395 and evaluating how concordant or divergent their views are with other stakeholders including 396 397 health care professionals, scientists and policy makers. This cumulative knowledge will be 398 used to develop an integrated foundation on the key factors requiring consideration when making decisions on the clinical utility, validity and (unintended) ramifications of selecting 399 400 conditions for genomic NBS.

As such, the study aligns with several pillars of the National Strategic Action Plan for Rare
Diseases, which sets the impetus for collaborative research to facilitate effective clinical
translation of health services (22). This study also reflects key national priorities that call for
engagement of affected individuals and their families to help harness the current and future
potential of genomics, facilitating processes for early diagnosis and ensuring that
implementation of novel (genomic) technologies is equitable and fit for the needs of
consumers (22).

Implementing genetic methodologies in newborn screening models undoubtedly provides a
platform for the early identification of medically actionable conditions, with the prospect of
changing disease trajectories and improving survival, function and quality of life for affected

newborns (39, 40). As such, the drive to introduce novel genomic NBS programs is becoming
increasingly apparent, with governmental initiatives, commercial and advocacy pressures all
creating a wide and mounting array of conditions that are technically capable of being
identified through population genetic screening in the newborn period (41).
However, underpinning these calls to action is a dearth of robust and high rigour evidence on

416 the impact and potential risks and opportunities that such genomic NBS programs will create, particularly as genetic testing in and of itself has far reaching and long-term implications on 417 not only affected individuals but also their families and the health system at large (42). Whilst 418 many genomic tests are valued for the diagnosis and monitoring of conditions, their use on a 419 population level (to screen for disease) has not always conferred a benefit on health 420 outcomes, quality of life or survival (42). The limitations of a technology centric approach to 421 NBS include ascertaining the predictiveness of genomic tests to account for the certainty and 422 timing of disease onset for some conditions, (the latter leaving a population that requires 423 proactive surveillance over the course of a lifetime, with the associated potential for 424 psychosocial implications of 'waiting for disease onset') (43-45), the dangers of including *en* 425 masse conditions in which there is no benefit from screening (46), the lack of reference 426 genetic data for variants in ethnically diverse populations and the use of genetic screening for 427 conditions where superior screening methods exist (42). These factors require careful 428 evaluation, so that a barometer for the harms of screening can be in place when making 429 health technology assessments, so as not to overstate the intended benefits. 430

Moreover, the processes that underpin genomics in NBS require specific consideration as
issues of public health ethics. These include, but are not limited to, considering how a
screening offer can be autonomously weighed by parents given the context of a likely
publicly funded universal test offer, the influence of solidarity i.e. the concept of standing for,
with and as newborns when thinking about the implications of this technology, rather than

just being led by the existence of new (genomic) technology, and the collective values of 436 reciprocity and trust to overcome inequities in access to novel technologies across the 437 population (47). The potential for stigma and discrimination and legal imperatives to counter 438 these effects are also important aspects to define and redress (48-50). 439 Through the evaluation and synthesis of stakeholder perspectives on the risks, benefits, 440 attitudes and expectations from genomic NBS, the findings from this study will generate new 441 knowledge to inform a model of genomic NBS that is adaptable to changing health 442 technologies, effective and of high quality, incorporates processes to mitigate and address 443 perceived harms and is placed within an ethically, legally and socially robust framework. 444 Furthermore, this study will be used to develop the rationale and key criterion for 445 implementing genomic NBS for conditions that differ in prevalence, disease characteristics 446 and genotype across the heterogenous Australian population, to help overcome barriers to 447 equity of access to novel (genetic) technologies and clinical care, as mandated by recent 448 governmental initiatives and health policy directives (51). By using the perspectives of 449 various key stakeholder communities to identify, consider and prioritise key utility, equity, 450 ethical and social issues, the study findings will feed directly into methodological 451 452 development in understanding the role of ethical, legal and social implications in HTA, improving transparency and fairness in health assessments (19, 52), whilst also placing 453 stakeholder perspectives within the decision-making process, as a means to address perceived 454 ethical and social complexities. 455

- 456
- 457
- 458
- 459

460 FUNDING

- 461 This study is part of the 'gEnomics4newborns: Integrating Ethics and Equity with
- 462 Effectiveness and Economics for genomic newborn screening' project funded by the
- 463 Commonwealth of Australia Medical Research Future Fund, grant MRF2015965.

464 DECLARATION OF INTERESTS

- 465 AJN is a member of the New South Wales Ministry of Health Newborn Screening Expert
- 466 Advisory Group. All other authors declare no competing interests.

467 ACKNOWLEDGEMENTS

- 468 This paper is submitted on behalf of the gEnomics4newborns Project Team including all
- 469 chief investigators, associate investigators, co-researchers, and partners.

470 AUTHOR CONTRIBUTIONS

471 The study was conceived and designed by SN, SK, JS, AJN, SC, MF and MO. SK, JS and

472 CM wrote the first draft of the manuscript before receiving input from SN, AJN, SC, MO,

473 MF, KB, JW, and NM. All authors have approved the final manuscript.

474

475

476

- 477
- 478
- 479

REFERENCES 481

Grosse SD, Boyle CA, Kenneson A, Khoury MJ, Wilfond BS. From public health emergency to 482 1. public health service: the implications of evolving criteria for newborn screening panels. Pediatrics. 483 2006;117(3):923-9. 484

485 Kingsmore SF, Smith LD, Kunard CM, Bainbridge M, Batalov S, Benson W, et al. A genome 2. 486 sequencing system for universal newborn screening, diagnosis, and precision medicine for severe 487 genetic diseases. American journal of human genetics. 2022;109(9):1605-19.

- 488 Powell CM. What Genomic Sequencing Can Offer Universal Newborn Screening Programs. 3. 489 The Hastings Center report. 2018;48 Suppl 2(Suppl 2):S18-s9.
- 490 Haendel M, Vasilevsky N, Unni D, Bologa C, Harris N, Rehm H, et al. How many rare diseases 4. 491 are there? Nature reviews Drug discovery. 2020;19(2):77-8.
- 492 5. Australian Bureau of Statistics Australian Demographic Statistics Dec 2018, cat. no. 3101.0. 493 https://www.abs.gov.au/ausstats/abs@.nsf/mf/3101.0.
- 494 6. Ji C, Farrar MA, Norris S, Bhattacharya K, Bennetts B, Newson AJ, et al. The Australian 495 landscape of newborn screening in the genomics era. 2023.
- 496 Haveems RZ, Miller FA, Barg CJ, Bombard Y, Cressman C, Painter-Main M, et al. Using 7. 497 Newborn Screening Bloodspots for Research: Public Preferences for Policy Options. Pediatrics. 498 2016;137(6).
- 499 8. Johnston J, Lantos JD, Goldenberg A, Chen F, Parens E, Koenig BA. Sequencing Newborns: A 500 Call for Nuanced Use of Genomic Technologies. The Hastings Center report. 2018;48 Suppl 2(Suppl 2):S2-s6. 501
- 502 9. Kariyawasam DST, Russell JS, Wiley V, Alexander IE, Farrar MA. The implementation of 503 newborn screening for spinal muscular atrophy: the Australian experience. Genetics in medicine : 504 official journal of the American College of Medical Genetics. 2020;22(3):557-65.
- 505 10. Farrar MA, Kariyawasam D, Grattan S, Bayley K, Davis M, Holland S, et al. Newborn Screening 506 for the Diagnosis and Treatment of Duchenne Muscular Dystrophy. Journal of neuromuscular 507 diseases. 2023;10(1):15-28.
- 508 Maron JL, Kingsmore S, Gelb BD, Vockley J, Wigby K, Bragg J, et al. Rapid Whole-Genomic 11. 509 Sequencing and a Targeted Neonatal Gene Panel in Infants With a Suspected Genetic Disorder. Jama. 510 2023;330(2):161-9.
- 511 12. Pichini A, Ahmed A, Patch C, Bick D, Leblond M, Kasperaviciute D, et al. Developing a
- 512 National Newborn Genomes Program: An Approach Driven by Ethics, Engagement and Co-design. 513 Front Genet. 2022;13:866168.
- 514 13. Australian Government: Department of Health And Aged Care What is screened in the 515 program: Conditions screened in Australia's NBS programs 4 Dec 2023.
- 516 https://www.health.gov.au/our-work/newborn-bloodspot-screening/what-is-screened.
- 517 14. Metternick-Jones SC, Lister KJ, Dawkins HJ, White CA, Weeramanthri TS. Review of current international decision-making processes for newborn screening: lessons for Australia. J Frontiers in 518 519 Public Health. 2015;3:214.
- 520 Australian Government Department of Health and Aged Care. Newborn Bloodspot Screening 15. 521 - National Policy Framework 21 May 2018.
- https://www.health.gov.au/resources/publications/newborn-bloodspot-screening-national-policy-522 523 framework?language=en.
- 524 Fischer KE, Grosse SD, Rogowski WH. The role of health technology assessment in coverage 16. 525 decisions on newborn screening. International journal of technology assessment in health care.
- 526 2011;27(4):313-21.
- 527 Bailey DB, Jr. The Krabbe Conundrum-How Are Benefits and Harms Weighed to Determine 17. 528 the Net Benefit of Screening? JAMA pediatrics. 2023;177(10):995-6.
- 529 Stark Z, Scott RH. Genomic newborn screening for rare diseases. J Nature Reviews Genetics 18.

medRxiv preprint doi: https://doi.org/10.1101/2024.02.11.24302654; this version posted February 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

530 2023;24(11):755-66.

Potter BK, Avard D, Entwistle V, Kennedy C, Chakraborty P, McGuire M, et al. Ethical, legal, 531 19. 532 and social issues in health technology assessment for prenatal/preconceptional and newborn 533 screening: a workshop report. Public health genomics. 2009;12(1):4-10.

534 20. Downie L, Halliday J, Lewis S, Amor D. Principles of genomic newborn screening programs: a 535 systematic review. J JAMA Network Open. 2021;4(7):e2114336-e.

536 Berg JS, Agrawal PB, Bailey DB, Jr., Beggs AH, Brenner SE, Brower AM, et al. Newborn 21. 537 Sequencing in Genomic Medicine and Public Health. Pediatrics. 2017;139(2).

538 Australian Government Department of Health National Strategic Action Plan for Rare 22. 539 Diseases 26 February 2020 https://www.health.gov.au/resources/publications/national-strategic-540 action-plan-for-rare-diseases.

541 23. Downie L, Halliday J, Lewis S, Amor DJ. Principles of Genomic Newborn Screening Programs: 542 A Systematic Review. JAMA network open. 2021;4(7):e2114336.

24. 543 Chan K, Hu Z, Bush LW, Cope H, Holm IA, Kingsmore SF, et al. NBSTRN Tools to Advance 544 Newborn Screening Research and Support Newborn Screening Stakeholders. International journal of 545 neonatal screening. 2023;9(4).

546 25. Armstrong B, Christensen KD, Genetti CA, Parad RB, Robinson JO, Blout Zawatsky CL, et al.

547 Parental Attitudes Toward Standard Newborn Screening and Newborn Genomic Sequencing: 548 Findings From the BabySeq Study. Front Genet. 2022;13:867371.

549 Lemke AA, Harris-Wai JN. Stakeholder engagement in policy development: challenges and 26. 550 opportunities for human genomics. Genetics in medicine : official journal of the American College of Medical Genetics. 2015;17(12):949-57. 551

552 27. Milko LV, Rini C, Lewis MA, Butterfield RM, Lin FC, Paquin RS, et al. Evaluating parents' 553 decisions about next-generation sequencing for their child in the NC NEXUS (North Carolina 554 Newborn Exome Sequencing for Universal Screening) study: a randomized controlled trial protocol. 555 Trials. 2018;19(1):344.

556 Timmins GT, Wynn J, Saami AM, Espinal A, Chung WK. Diverse Parental Perspectives of the 28. 557 Social and Educational Needs for Expanding Newborn Screening through Genomic Sequencing. 558 Public health genomics. 2022:1-8.

559 29. White S, Mossfield T, Fleming J, Barlow-Stewart K, Ghedia S, Dickson R, et al. Expanding the 560 Australian Newborn Blood Spot Screening Program using genomic sequencing: do we want it and are 561 we ready? European journal of human genetics : EJHG. 2023;31(6):703-11.

Gold NB, Adelson SM, Shah N, Williams S, Bick SL, Zoltick ES, et al. Perspectives of Rare 562 30. 563 Disease Experts on Newborn Genome Sequencing. JAMA network open. 2023;6(5):e2312231.

564 31. Stojanovic J, Wübbeler M, Geis S, Reviriego E, Gutiérrez-Ibarluzea I, Lenoir-Wijnkoop I. Evaluating Public Health Interventions: A Neglected Area in Health Technology Assessment. Frontiers 565 566 in public health. 2020;8:106.

O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative 567 32. research: a synthesis of recommendations. J Academic Medicine. 2014;89(9):1245-51. 568

569 33. Dworkin SL. Sample size policy for qualitative studies using in-depth interviews. Arch Sex 570 Behav. 2012;41(6):1319-20.

571 34. Lynch F, Best S, Gaff C, Downie L, Archibald AD, Gyngell C, et al. Australian Public

572 Perspectives on Genomic Newborn Screening: Risks, Benefits, and Preferences for Implementation. 573 International journal of neonatal screening. 2024;10(1).

Brehaut JC, O'Connor AM, Wood TJ, Hack TF, Siminoff L, Gordon E, et al. Validation of a 574 35. decision regret scale. Medical decision making : an international journal of the Society for Medical 575 576 Decision Making. 2003;23(4):281-92.

577 Vears DF, Gillam L. Inductive content analysis: A guide for beginning qualitative researchers. 36. 578 J Focus on Health Professional Education: A Multi-disciplinary Journal. 2022;23(1):111-27.

579 37. Eisikovits Z, Koren C. Approaches to and outcomes of dyadic interview analysis. Qualitative 580 health research. 2010;20(12):1642-55.

medRxiv preprint doi: https://doi.org/10.1101/2024.02.11.24302654; this version posted February 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

581 38. Cao M, Notini L, Ayres S, Vears DF. Australian healthcare professionals' perspectives on the 582 ethical and practical issues associated with genomic newborn screening. Journal of genetic 583 counseling. 2023;32(2):376-86.

584 39. Kariyawasam DS, D'Silva AM, Sampaio H, Briggs N, Herbert K, Wiley V, et al. Newborn 585 screening for spinal muscular atrophy in Australia: a non-randomised cohort study. The Lancet Child 586 & adolescent health. 2023;7(3):159-70.

587 Yang L, Chen J, Shen B. Newborn Screening in the Era of Precision Medicine. Advances in 40. 588 experimental medicine and biology. 2017;1005:47-61.

Ersig AL, Jaja C, Tluczek A. Call to Action for Advancing Equitable Genomic Newborn 589 41. 590 Screening. J Public Health Genomics. 2023;26(1):188-93.

591 42. Turnbull C, Firth HV, Wilkie AO, Newman W, Raymond FL, Tomlinson I, et al. Population 592 screening requires robust evidence—genomics is no exception. J The Lancet. 2023.

593 Raj A, Rifkin SA, Andersen E, van Oudenaarden A. Variability in gene expression underlies 43. 594 incomplete penetrance. Nature. 2010;463(7283):913-8.

595 44. Mirshahi UL, Colclough K, Wright CF, Wood AR, Beaumont RN, Tyrrell J, et al. Reduced 596 penetrance of MODY-associated HNF1A/HNF4A variants but not GCK variants in clinically unselected 597 cohorts. American journal of human genetics. 2022;109(11):2018-28.

598 45. Horton R, Lucassen A. Ethical issues raised by new genomic technologies: the case study of 599 newborn genome screening. J Cambridge Prisms: Precision Medicine. 2023;1:e2.

600 46. Wilson JMG, Jungner G, Organization WH. Principles and practice of screening for disease. 601 1968.

Newson AJ. The promise of public health ethics for precision medicine: The case of newborn 602 47. 603 preventive genomic sequencing. J Human Genetics. 2022;141(5):1035-43.

Vears DF, Savulescu J, Christodoulou J, Wall M, Newson AJ. Are We Ready for Whole 604 48. 605 Population Genomic Sequencing of Asymptomatic Newborns? Pharmacogenomics and personalized 606 medicine. 2023;16:681-91.

607 King JR, Grill K, Hammarström L. Genomic-Based Newborn Screening for Inborn Errors of 49. 608 Immunity: Practical and Ethical Considerations. International journal of neonatal screening. 609 2023;9(2).

610 50. Newson AJ, Ayres S, Boyle J, Gabbett MT, Nisselle A. Human genetics Society of Australasia 611 Position Statement: genetic testing and personal insurance products in Australia. Twin Research and Human Genetics. 2018;21(6):533-7. 612

Stark Z, Boughtwood T, Haas M, Braithwaite J, Gaff CL, Goranitis I, et al. Australian 613 51.

614 Genomics: Outcomes of a 5-year national program to accelerate the integration of genomics in 615 healthcare. American journal of human genetics. 2023;110(3):419-26.

616 Jansen ME, Lister KJ, van Kranen HJ, Cornel MC. Policy Making in Newborn Screening Needs 52. 617 a Structured and Transparent Approach. Frontiers in public health. 2017;5:53.

Knowledge inquiry & synthesis

Co-developing tools for an Australian context

Evaluation and implementation



Consultation with stakeholders* to assess their priorities, attitudes and concerns regarding genomic NBS including the relative importance, facilitators and barriers of legal, social, ethical, and equity considerations



Explore and test how ethics and equity factors can be incorporated in HTA for genomic NBS, using a multimodal approach**



Develop key assessment criteria to inform accelerated and patient/family centred decision making for conditions that have the potential to be part of genomic NBS



Build and test an economic model for genomic NBS, explicitly incorporating aspects of equity





Development of policyrelevant tools to support streamlined, less resourceintensive health technology assessments of new conditions for genomic NBS, that explicitly take account of the ethical, legal, sociocultural and equity aspects of genomics